-
LDL versus inflammation: what remains after aggressive lipid lowering?
Oh-sung Kwon The Catholic University of Korea, Republic of Korea 13:00~13:18 -
Emerging anti-inflammatory therapies in ASCVD: canakinumab, NLRP3 inhibitors, and beyond
Sung-A Bae Yonsei University, Republic of Korea 13:18~13:36 -
Colchicine for secondary prevention in ASCVD
Dae Young Cheon Hallym University, Republic of Korea 13:36~13:54 -
Immune mechanisms of residual cardiovascular risk: from oxidation-specific epitopes to therapeutic targets
Christoph J. Binder Medical University of Vienna, Austria 13:54~14:12 - Panel Discussion 14:12~14:30
Chairperson(s) : Hayato Tada (Kanazawa University, Japan)
-
Refined risk assessment in FH
Sayaka Funabashi Kyorin University, Japan 14:30~14:48 - Q&A 14:48~14:52
-
Cause of death in FH
Chan Joo Lee Yonsei University, Republic of Korea 14:52~15:10 - Q&A 15:10~15:14
-
Experience on new drugs for FH: including lomitapide & evinacumab
Hayato Tada Kanazawa University, Japan 15:14~15:32 - Q&A 15:32~15:36
-
Genome editing for precision medicine
HyongBum Kim Yonsei University, Republic of Korea 15:36~15:54 - Q&A 15:54~15:58
-
Do East Asians need lower statin intensity? ethnic differences in LDL-C response and safety
Eun Jeong Cho Chung-Ang University, Republic of Korea 16:10~16:28 -
Why TG is important in Asians?
Daisaku Masuda Rinku General Medical Center, Japan 16:28~16:46 -
Genetic stratification and treatment response in Korean severe hypertriglyceridemia: a prospective multicenter registry study
Hun Jee Choe Hallym University, Republic of Korea 16:46~17:04 -
Chylomicronemia: past, present and future
Hiroaki Okazaki Teikyo University, Japan 17:04~17:22 - Panel Discussion 17:22~17:40
-
Bempedoic acid: LDL-C lowering beyond statins - evidence and clinical role
Che Wan Lim Catholic Kwandong University, Republic of Korea 08:30~08:50 -
Optimizing non-statin therapy: PCSK9 inhibitors and inclisiran
TBD (Name) TBD (Affiliation, Country) 08:50~09:10 -
Emerging Lp(a)-lowering therapies: siRNA, ASO, and beyond
Yu-Chen Wang Asia University, Taiwan 09:10~09:30 - Panel Discussion 09:30~10:00
-
Lipoprotein(a) in Korean patients: real-world data, cardiovascular risk, and clinical implications
Sang Min Park Eulji University, Republic of Korea 13:45~14:05 -
Lipoprotein(a) and coronary atherosclerosis in Vietnam: real-world data and emerging cardiovascular risk
Tien Hoang Anh Hue University, Vietnam 14:05~14:25 -
Measuring Lipoprotein(a) in clinical practice: assay challenges, standardization, and interpretation
Sang Guk Lee Yonsei University, Republic of Korea 14:25~14:45 - Panel Discussion 14:45~15:15
-
CETP inhibition revisited: obicetrapib for LDL-C reduction and ASCVD risk management
Mariko Harada-Shiba Osaka Medical and Pharmaceutical University, Japan 16:10~16:30 -
APOC3 inhibition: targeting triglyceride-rich lipoproteins and residual risk
Jin Wi Gachon University, Republic of Korea 16:30~16:50 -
ANGPTL3 inhibition: expanding therapeutic opportunities beyond LDL-C
Hye Moon Chung Kyung Hee University, Republic of Korea 16:50~17:10 - Panel Discussion 17:10~17:40
-
The emerging role of ApoB and triglyceride-rich lipoproteins
Sin Yung Woo Konyang University, Republic of Korea 08:50~09:10 -
Beyond LDL-C: targeting inflammation and lipoprotein(a) to address residual cardiovascular risk in Asia
Ping-Yen Liu National Cheng Kung University, Taiwan 09:10~09:30 -
Cardiometabolic residual risk in Asia: diabetes, metabolic dysfunction, and vascular aging
Minkwan Kim Yonsei University, Republic of Korea 09:30~09:50 - Panel Discussion 09:50~10:20
-
Impact of lipid-lowering therapy on plaque stabilization and regression
Jong Young Lee Hallym University, Republic of Korea 13:00~13:15 -
Coronary microvascular dysfunction after PCI
Hyun Sung Joh Seoul National University, Republic of Korea 13:15~13:30 -
Discordance between CAC and coronary stenosis
TBD (Name) TBD (Affiliation, Country) 13:30~13:45 - Panel Discussion 13:45~14:00
-
AI-CVD: opportunistic testing of coronary calcium and beyond
Nathan D. Wong University of California, Irvine, USA 14:10~14:28 -
From physics to physiology: computational hemodynamics and coronary flow modeling in atherosclerosis
Joon Sang Lee Yonsei University, Republic of Korea 14:28~14:46 -
Application of AI to coronary angiography
Si-Hyuck Kang Seoul National University, Republic of Korea 14:46~15:04 -
AI-based retinomics: cardiovascular risk prediction using retinal imaging
Sahil Thakur Medical Affairs, Mediwhale Inc., Singapore 15:04~15:22 - Panel Dicsussion 15:22~15:40
-
ESC/EAS dyslipidemia guidelines: recent updates and evidence base
Meral Kayikcioglu Ege University, Türkiye 15:40~16:00 -
Korean perspectives on dyslipidemia guidelines: recent update and challenges
Jaehoon Chung Gachon University, Republic of Korea 16:00~16:20 -
Translating guidelines into practice
Wonjin Kim Cha University, Republic of Korea 16:20~16:40 - Panel Discussion 16:40~17:10
